BioPharmSignal logoBioPharmSignal

Biotech News

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

Brainstorm Cell Therapeutics Inc. (BCLI)Brainstorm Cell Therapeutics Inc.FDA / regulatory

BCLI (BCLI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bcli.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-07-28 12:00 EST

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

BCLIBrainstorm Cell Therapeutics Inc.2026-08-24 12:15 EST

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

CGTXCognition Therapeutics2026-09-29 11:30 EST

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

GANXGain Therapeutics2026-06-29 20:05 EST

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

CGTXCognition Therapeutics2026-06-24 11:30 EST

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

PRAXPraxis Precision Medicines2026-06-29 20:30 EST

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

TEVATeva Pharmaceutical Industries2026-08-19 12:30 EST

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

ACIUAC Immune2026-08-11 11:00 EST

AC Immune Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)

View all latest news

Brainstorm Cell Therapeutics Inc.

Autologous Cell-Therapy Developer BrainStorm Cell Therapeutics is developing autologous cellular therapies for neurodegenerative diseases. Its programs use a patient's own cells to deliver neuroprotective and immunomodulatory factors in disorders characterized by progressive neuronal damage. NurOwn Technology NurOwn, also known as...

Recent company news

BCLIBrainstorm Cell Therapeutics Inc.2026-08-24 12:15 EST

BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions

BCLIBrainstorm Cell Therapeutics Inc.2026-08-14 20:00 EST

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BCLIBrainstorm Cell Therapeutics Inc.2026-07-28 12:00 EST

BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman

BCLIBrainstorm Cell Therapeutics Inc.2026-06-02 13:00 EST

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

BCLIBrainstorm Cell Therapeutics Inc.2026-05-28 11:45 EST

BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors

Stock data

Close
1.00 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States